Market News for Pfizer Inc (PFE)
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE....
Zacks Investment Research - 5/22/2026 11:05:22 AM
More News for PFE
Stock Analysis for PFE
Related Stocks:
PFE's aggressive M&A and in-house R&D efforts are paying off, with the growth portfolio (newly launched/acquired products) already delivering $3.1B in revenues in FQ1'26 (+22% YoY operationally). LOE risks are mitigated by delayed Vyndamax generic entry to mid-2031, supporting the management's high single-digit 5Y revenue growth guidance from 2029 onwards. PFE's intermediate-term performance is expected to remain lumpy, but the cost saving efforts, strong interest coverage, and dividend sustainability underpin its compelling investment thesis....
Seeking Alpha - 5/22/2026 7:19:32 AM
More News for PFE
Stock Analysis for PFE
Related Stocks:
